The consensus price target hints at a 100.4% upside potential for 908 Devices Inc. (MASS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the foll

908 Devices: Not Worth Investing

07:49am, Thursday, 31'st Aug 2023
908 Devices announced Q2 FY23 results with an 8.9% increase in revenue, driven by a 27% increase in MX908 device sales. The company experienced a significant drop in gross profit margin and an increas
Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
908 Devices, Inc. (NASDAQ:MASS ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - Co-Founder, CEO, President & Director Joseph Griffith - C
908 Devices Inc. (MASS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.26 per share a year ago.
908 Devices Inc. (MASS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
908 Devices Inc. (MASS) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.30 per share a year ago.
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the four
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE